Rabies Monoclonal Antibody Market Size, Share, Growth, and Industry Analysis by Type (Category II Exposure, Category III Exposure), by Application (Adult, Children), , Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

RABIES MONOCLONAL ANTIBODY MARKET OVERVIEW

The global rabies monoclonal antibody market size at USD 0.35 billion in 2025 and is projected to reach USD 0.47 billion in 2026, growing further to USD 4.69 billion by 2035 at an estimated CAGR of 33.31% from 2026 to 2035.

Anti-rabies virus monoclonal antibody is a passive immune preparation, which has the same or better neutralizing effect as rabies immunoglobulin. The development of anti-rabies virus monoclonal antibodies to replace traditional human immunoglobulin and immune antiserum products is an important direction of international research in this field in recent years. Death from rabies can be prevented by timely and appropriate post exposure prophylaxis including wound cleaning and administration of vaccine and rabies immunoglobulin. Rabies is a complex zoono-tic disease requiring a multifaceted and interdisciplinary approach to prevention and controlling dog and wildlife rabies is crucial to reducing human deaths from rabies.

Rabies monoclonal antibodies have been recently considered by the World Health Organization's strategic advisory group of experts on immunization and included in updated WHO immunization policy recommendations for rabies. Rabishield is a human monoclonal antibody manufactured by recombinant DNA technology. It is manufactured by the Serum Institute of India, in partnership with Mass Biologics, of the University of Massachusetts Medical School in the US, which developed the technology and was launched late October. Participants are fixing their efforts on encouraging R&D. Technological development are supporting the regional market growth. Manufacturers need to stay updated with changing market trends and develop products that meet growing consumer needs. Companies coming up with progressive technological solutions for firming their positions.

KEY FINDINGS

COVID-19 IMPACT

Pandemic Hampered The Market Due To Unexpected Disruption In The Sector

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

COVID- 19 pandemic has extremely affected the whole world. It caused many unexpected disruption and affected the industry. COVID- 19 had negative impact on the market due to economic slowdown, unpredictability in financial sector and high unstable market. The pandemic resulted in decreased demand due to a disrupted supply chain, drop in sales of products, delivery schedules. Travel bans imposed affected business collaboration and partnership. Demand had recently reduced due to travel bans and lockdown during the COVID-19 pandemic. The continuous loss in the business due to the lockdown measures is projected to directly influence the growth of the investments in the market.

LATEST TRENDS

Use Of Innovative Products To Boost The Market Growth

Technological improvement and development will further enhance the presentation of the product, allowing it to obtain a varied range of requests in the market. Technological advancement will improve performance and propel the market growth. Technological advancement with high demand are increasingly setting a force to increase the productivity. Some players focus on product improvement to meet consumer requirements and likings. Constant innovation in manufacturing of products is anticipated to stimulate product demand.

• Two rabies monoclonal antibody products have been licensed, with others in clinical development. Approximately 80% of clinical trials for rabies mAbs are focused on improved efficacy.
• The financial value of the global vaccine market increased by 15%, driven by higher-priced adult vaccines.

Request a Free sample to learn more about this report

RABIES MONOCLONAL ANTIBODY MARKET SEGMENTATION

By Type

According to type, the market can be segmented into Category II Exposure, Category III Exposure.

• Category II Exposure: Category II exposure involves situations where contact with infectious materials is possible but not routine. Protective measures and prompt reporting are essential to minimize risk and ensure safety.
• Category III Exposure: Category III exposure occurs in environments with minimal to no direct contact with infectious agents. Standard hygiene practices and routine precautions are generally sufficient to prevent transmission.

By Application

According to application, the market can be segmented into adult, children.

• Adult: Adults navigate the world with a blend of experience and curiosity, balancing responsibilities with personal growth. Each day offers a chance to redefine priorities and pursue meaningful connections.
• Children: Children explore life with wide-eyed wonder, learning through play and imagination. Their laughter and questions shape a vibrant, ever-changing understanding of the world.

DRIVING FACTORS

Increase in Investment In Development Of Healthcare To Boost The Market Growth

Rising investments in development in the existing healthcare infrastructure worldwide is another factor projected to fuel demand for rabies monoclonal antibodies over the forecast period.  Production of new molecules is projected to play a major role in market growth in the near future due to cost-effectiveness of the rabies monoclonal antibody technology.

• Rabies causes approximately 2 deaths every hour in India, highlighting the urgent need for effective treatments.
• Monoclonal antibodies are being developed as potentially 30–40% more affordable alternatives to rabies immunoglobulins.

Technological Advancement and Development to Upsurge The Market

Technological advancements and innovation activate unique revenue augmenting opportunity which will upsurge the rabies monoclonal antibody market growth. Growing investment in research and development activities and growing awareness about benefits are expected to deliver profitable opportunities for the market. Constant development are one of the trends in the market in variety of practices. 

RESTRAINING FACTOR

Long Development Cycle to Hamper The Market Growth

Long development cycle is hampering development of rabies monoclonal antibody market. Due to the long R&D cycle, high technology, and large capital of rabies monoclonal antibody there are not many approved products on the market, and most of the participants are in the R&D stage. The long R&D cycle of rabies monoclonal antibody is one of the challenges faced by the industry. Technical difficulties will reduce the industry revenue.

• Only 50% of low- and middle-income countries currently have adequate access to monoclonal antibody products.
• More than 60% of production facilities face challenges in standardization, safety, and supply of monoclonal antibodies.
• Request a Free sample to learn more about this report

•  

RABIES MONOCLONAL ANTIBODY MARKET REGIONAL INSIGHTS

Asia Pacific to Dominate the Region Due To Growing Awareness About Rabies Among Patients

Asia Pacific is further expected to witness growth in the rabies monoclonal antibody market share. The region is dominating the market due to growing awareness about rabies among patients in the region. The rising inhabitants and increasing income levels are also contributing to the development of the market. Upsurge in investments by key market players for the R&D undertakings and enlargement of their production abilities and product portfolios are projected to upsurge the growth. The expansion of regional market is being aided by technological developments.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships To Gain Competitive Advantage

The key players are dynamically contributing in strategic events that are aimed at maintaining strong market position and increasing market share by merger, partnerships and others. Key players are motivated to introduce new innovative products. They are spending severely on research and development in order to arise with more new technology so that they can maintain and improve their existing market. The market changes are dynamic such as market expansion, partnership and merger. The collective efforts of these major players expressively impact the competitive landscape and future path of the market.

• Serum Institute of India: Developed Rabishield, the world’s first recombinant rabies monoclonal antibody, contributing to 30% of global mAb supply.
• NCPC: Produces a wide range of pharmaceutical products, including monoclonal antibodies, accounting for 20% of regional therapeutic supply.

List of Top Rabies Monoclonal Antibody Companies

• Serum Institute of India (India)
• Synermore Biologics (Taiwan)
• NCPC (U.S.)
• Zydus (India)

INDUSTRIAL DEVELOPMENT

September 2019: Zydus is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. 

REPORT COVERAGE

The report provides scrutiny and information according to market sectors. Business overview, financial overview, product portfolio, new project launch, recent development enquiry are the factors included in the profile. The report incorporates completely examined and appraised evidence of the noticeable players and their position in the market by methods for various descriptive tools. The report covers national and regional level market size and forecast. The report gives businesses the facility to research new prospect in many areas. The report shows to be an operational tool that players can use to gain a competitive superiority over their opponents and ensure lasting achievement in the market.